Sinopharm says its vaccine can develop “strong antibodies” against the Delta variant

Chinese vaccine manufacturers Sinopharm claim that it’s vaccines can create strong antibodies against the new ‘Delta’ variant of COVID-19

This is according to a report from Global Times.

Chinese researchers led by Yang Xiaoming, chairman of Sinopharm China National Biotec Group, a subsidiary of Sinopharm, have found that its vaccine, Sinopharm, could develop antibodies or monoclonal antibodies that can block the binding of coronavirus to an enzyme known as ACE 2 (Angiotensin-converting enzyme 2).